Aids Behind Closed Doors 1995. BBC Horizon and a Plague in the Wind Aired 29 October 1984. Biological warfare to Psyops. White Board Brainstorm post #CovidPurpose #THESLOG #UKCOLUMN @FINANCIALEYES @JOEBLOB20 #COVIDPURPOSE @CLARKEMICAH #CONQUESTOFDOUGH @WIKI_BALLOT

Selection_584

Selection_585

https://archive.org/details/BBCHorizonCollection512Episodes/BBC+Horizon+-+s1995e19+-+AIDS+Behind+Closed+Doors.avi

AIDS, Behind Closed Doors” 4 December 1995 BBC2’s Red Ribbon season continues with a special edition of Horizon, which goes behind closed doors to a meeting of leading international figures in Aids research. Journalist Oliver Morton and development expert Susan George report on new thinking in the continuing battle against Aids. See today’s choices. Produce Andrew Chitty ; Editor John Lynch TRANSCRIPT: please send cheque for £2.50, payable to BSS. to: [address removed] Please allow 28 days for delivery. The Red Ribbon season continues tomorrow with Fine Cut at 9.00pm Contributors: Synopsis Special edition of HORIZON going behind closed doors of a meeting of international AIDS researchers. Cast & Credits Cast presenter Oliver Morton presenter Susan George Credits Unknown: Producer Andrew Chitty Editor John Lynch Transmission Company BBC Television https://www.bfi.org.uk/films-tv-people/4ce2b7ed9a2fe

created at TagCrowd.com
 

David Ho

From Wikipedia, the free encyclopedia

Jump to navigationJump to search

David Ho
David Ho
Ho photo.jpg
Born November 3, 1952 (age 67)

Other names David Da-i Ho
Education California Institute of Technology (BS)
Massachusetts Institute of Technology (MD)
Employer Aaron Diamond AIDS Research CenterColumbia University
Known for AIDS research
Partner(s) Tera Man Wong
Children 4

David Da-i Ho (Chinese何大一; born November 3, 1952) is a Taiwanese-American doctor and HIV/AIDS researcher who has made many scientific contributions to the understanding and treatment of HIV infection.[1][2][3][4][5]

He is the founding scientific director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University.

David Ho was born in TaichungTaiwan, to Paul (何步基Hé Bùjī, an engineer) and Sonia Ho (Jiang) (江雙如Jiāng Shuāngrú). David Ho attended Taichung Municipal Guang-Fu Elementary School until sixth grade before immigrating to the United States with his mother and younger brother to unite with his father, who had already been in the US since 1957. He grew up in Los Angeles and graduated from John Marshall High School. He received his Bachelor of Science in biology with highest honors from the California Institute of Technology (1974)[6] and MD from the Harvard-MIT Division of Health Sciences and Technology (1978). Subsequently, he did his clinical training in internal medicine and infectious diseases at UCLA School of Medicine (1978–1982) and Massachusetts General Hospital (1982–1985), respectively. He was a resident in internal medicine at Cedars-Sinai Medical Center in Los Angeles in 1981 when he came into contact with some of the first reported cases of what was later identified as AIDS.

Career[edit]

Dr. Ho has been engaged in HIV/AIDS research since the beginning of the epidemic, initially focusing on clinical virology and select topics in HIV pathogenesis. In the mid 1990s, his research team conducted a series of elegant human studies to elucidate the dynamics of HIV replication in vivo. This knowledge, in turn, formed the foundation for their pioneering effort to treat HIV “early and hard” and in demonstrating for the first time the durable control of HIV replication in patients receiving combination antiretroviral therapy. This was the turning point in the epidemic that an automatic death sentence was transformed into a manageable disease.

For the past decade and a half, Dr. Ho has shifted his research focus to developing strategies to prevent HIV transmission. A protective vaccine against HIV remains elusive despite concerted research efforts. However, Dr. Ho has been leading non-vaccine approaches to block HIV transmission that have shown considerable promise. His group was the first to demonstrate protective efficacy of a long-acting antiretroviral drug as pre-exposure prophylaxis in rhesus macaques. In fact, one such agent, cabotegravir, has been advanced into Phase-3 efficacy trials in high-risk populations, in collaboration with GlaxoSmithKline. In parallel, Dr. Ho’s group has also engineered exquisitely potent antibodies that neutralize divergent strains of HIV. The most promising neutralizing agent is a bispecific monoclonal antibody that entered a first-in-human clinical trial in 2019 with the support of the Bill & Melinda Gates Foundation. The Ho Lab is funded by two NIH grants to pursue the use of engineered antibodies to purge the viral latent reservoir as a part of the international HIV cure effort. Currently, the Ho lab is funded by the Jack Ma Foundation to work on coronavirus projects.

Ho has published more than 500 research papers as of February 2020.[7] He championed the combination anti-retroviral therapy[8] which had earlier been developed by scientists at NIAID and Merck.[9] This approach allowed the control of HIV replication in patients.[10]

Ho is a member of the Committee of 100, a Chinese American leadership organization, in addition to several scientific groups.[11]

Ho is leading a team, funded by Jack Ma, to look for a vaccine for the COVID-19 virus [12] and believes that other treatments that may become effective against COVID-19 should be examined.[13]

Robin Weiss

From Wikipedia, the free encyclopedia

Jump to navigationJump to search

Robert Anthony “Robin” Weiss (born 20 February 1940[1]) is a British molecular biologist,[2] Professor of Viral Oncology at University College London[3] and a member of the Nuffield Council on Bioethics.[4]

Research[edit]

His research has focussed on retroviruses, initially as a means of understanding T-cell leukemia and other cancers, which may be caused by retroviruses. A break-through discovery in 1971 was that the retroviral genome in chickens follows the rules of Mendelian inheritance.[5] Later his work moved on to HIV, also a retrovirus, and made several new important discoveries, most notably identifying CD4 on lymphocytes as the binding receptor for HIV.[5]

Career[edit]

Before becoming professor at UCL, Weiss was Director at The Institute of Cancer Research, London, from 1980 until 1989, after which he continued as Director of Research for a further nine years.[6]

Until 2005, Weiss was Editor-in-Chief of the British Journal of Cancer. His successor, A. L. Harris, states that Weiss showed “clear vision in developing the British Journal of Cancer into [a] multidisciplinary journal with a focus on research that aims to deliver benefits to cancer patients.”[7]

Awards and recognition[edit]

In 1977, Weiss was elected a member of the European Molecular Biology Organization.[8] He became a Fellow of the Royal Society in 1997, and in 1999 he became an Honorary Fellowship of the Royal College of Physicians.[8]

In November 2001, the Royal Netherlands Academy of Arts and Sciences awarded Weiss the M. W. Beijerinck Prize for Virology, noting especially his work on retroviruses.[9] In the same year, he delivered the Leeuwenhoek Lecture.[10]

In 2007, Imperial College London awarded Weiss the Ernst Chain Prize, noting that he “has pioneered our understanding of HIV and AIDS, particularly on the identification of CD4 as the HIV receptor and on the analysis of neutralizing antibodies to the virus” [11]

Weiss was elected as Honorary Member of the Microbiology Society in 2009.[12] He is a member of the European Academy of Microbiology (EAM).[13] He was elected to the American Philosophical Society in 2018.[14]

Obituary

Norman Letvin 1949–2012

Norman Letvin lost his long fight with pancreatic cancer on 28 May 2012. The field of HIV-AIDS immunology has lost one of its founding fathers and one of its most clear-sighted and rigorous minds.

Dani P. Bolognesi

DANI P. BOLOGNESI is a Founder of Trimeris, Inc., has been a Director
since its inception and was named Chief Executive Officer and Chief
Scientific Officer in March 1999. Dr. Bolognesi held a number of
positions at Duke University from 1971 to March 1999, and served as
James B. Duke Professor of Surgery, Professor of
Microbiology/Immunology, Vice Chairman of the Department of Surgery for
Research and Development and Director of the Duke University Center for
AIDS Research from 1989 to March 1999. From 1988 to March 1999, Dr.
Bolognesi was the Director of the Central Laboratory Network that
supports all HIV vaccine clinical trials sponsored by the National
Institutes of Health. Dr. Bolognesi received his PhD degree in Virology
from Duke University.

Related Interviews:

Dani Bolognesi – Trimeris Inc (trms)
October 12, 2001

Dani Bolognesi – Trimeris Inc (trms)
September 14, 2001

With $115 million, more than 80 Boston researchers will collaborate to tackle COVID-19

A $115 million collaboration to tackle the rapidly spreading viral disease COVID-19, led by heavy hitters of Boston science and funded by a Chinese property development company, kicked off today as the group’s leaders pledged to take on the virus on many fronts. The project brings together researchers at many of the city’s top academic institutions, along with local biotechnology companies such as Moderna. Those leading it hope they can quickly funnel money into studies that will build off a new repository of samples from infected people and community surveillance, materials that can be rapidly shared among scientists. The project, they anticipate, should answer critical questions about how COVID-19 is spreading and how best to prevent and treat infections.

“It was time to harness the whole breadth of knowledge that’s available” in the Boston region, says immunologist Bruce Walker, a leader in HIV/AIDS research; director of the Ragon Institute of MGH, MIT, and Harvard; and joint head of the collaboration. He leads the project with Arlene Sharpe, co-director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. Walker and Sharpe were among more than 80 scientists and clinicians who met Monday at Harvard Medical School—in person or, in the case of collaborators in China, remotely—to hammer out the details of the effort, including how to prioritize funding needs.

PMCID: PMC4312487
NIHMSID: NIHMS647758
PMID: 25526311

Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis

Jonathan Mann (WHO official)

Jonathan Max Mann (July 30, 1947 – September 2, 1998) was an American physician who was an administrator for the World Health Organization, and spearheaded early AIDS research in the 1980s.

Education[edit]

Mann was president of the National Honor Society in the Newton South High School class of 1965. He earned his B.A. magna cum laude from Harvard College, his M.D. from Washington University in St. Louis (1974), and the degree of M.P.H. from the Harvard School of Public Health in 1980.[2]

Career[edit]

Mann joined the Centers for Disease Control in 1975, staying there until 1977 when he became the State Epidemiologist for New Mexico, until 1984.[2]

He moved to Zaire in March 1984 as a founder of Project SIDA, an effort to study AIDS in Africa, after being recruited by fellow epidemiologist Joseph B. McCormick.[3] In 1986 he founded the WHO’s Global Programme for AIDS, resigning this post in 1990 to protest the lack of response from the United Nations with regard to AIDS, and the actions of the then WHO director-general Hiroshi Nakajima.[4]

In 1990, Mann founded the health and human rights organization HealthRight International (initially known as Doctors of the World-USA), to fill a void he perceived amongst the health and human rights organizations in the United States and to create a unique organization whose mission was to create sustainable programs that promote and protect health and human rights in the United States and abroad.[5]

Mann directed the launch in 1994 of the journal [1]Health and Human Rights (journal), published by the François Xavier Bagnoud Center for Health and Human Rights, which he also helped to establish.[2]

Promoting health and human rights[edit]

Mann was a pioneer in advocating combining public health, ethics and human rights. He theorized and actively promoted the idea that human health and human rights are integrally and inextricably connected, arguing that these fields overlap in their respective philosophies and objectives to improve health, well-being, and to prevent premature death.[6]

Mann proposed a three-pronged approach to the fundamental issue of the relationship between health and human rights. First, health is a human rights issue. Secondly (and conversely), human rights are a health issue. Human rights violations result in adverse health effects.[7] Thirdly, linkages exist between health and human rights (a hypothesis to be rigorously tested).[8] Literature substantiates the effects of the first two points, but Mann and colleagues proceeded to call for the validation of the third point and challenged the world to practice it.[9] His work led to the development of the Four-Step Impact Assessment, a multi-disciplinary approach of evaluating interdependent and overlapping elements of both disciplines of human rights and Public Health.

With this framework, Mann attempted to bridge a perceived gap of philosophies, correspondence and vocabulary, education and training, recruitment, and work methods between the disciplines of bioethicsjurisprudencepublic health law and epidemiology. Furthermore, Mann knew that the history of “conflictual relationships” between officials of public health and civil liberties workers presented challenges to the pursuit of what he called a “powerful” confluence of health and human rights – a positive approach.[10]

Death[edit]

Mann died in the 1998 crash of Swissair Flight 111 along with his second wife, AIDS researcher Mary Lou Clements-Mann.[4] At the time of his death, Mann was the dean of the Allegheny University School of Public Health (now Drexel University School of Public Health) in Philadelphia.

Bibliography[edit]

External links[edit]

Swissair Flight 111

Swissair Flight 111 was a scheduled international passenger flight from John F. Kennedy International Airport in New York City, United States, to Cointrin International Airport in Geneva, Switzerland. This flight was also a codeshare flight with Delta Air Lines.[2] On 2 September 1998, the McDonnell Douglas MD-11 performing this flight, registration HB-IWF, crashed into the Atlantic Ocean southwest of Halifax International Airport at the entrance to St. Margarets Bay, Nova Scotia. The crash site was 8 kilometres (5 mi; 4 nmi) from shore, roughly equidistant from the tiny fishing and tourist communities of Peggy’s Cove and Bayswater. All 229 passengers and crew on board the MD-11 were killed, making the crash the deadliest McDonnell Douglas MD-11 accident in aviation history.[3]

The search and rescue response, crash recovery operation, and investigation by the Government of Canada took more than four years and cost $57 million CAD.[4] The investigation carried out by the Transportation Safety Board of Canada (TSB) concluded that flammable material used in the aircraft’s structure allowed a fire to spread beyond the control of the crew, resulting in the crash of the aircraft. Several wide-ranging recommendations were made which have been incorporated into new US Federal Aviation Administration standards.[1]:253

Swissair Flight 111 was known as the “UN shuttle” because of its popularity with United Nations officials; the flight also carried business executives, scientists, and researchers.[5]

Selection_587

created at TagCrowd.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.